Plain-English translation of NCT05392387 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing three different ways to treat chronic hepatitis B infection. Some participants will take peg-IFN-alpha alone, some will take nucleos(t)ide analogues alone, and some will take both medications together. The study will track how well each approach works and look at factors that help predict which patients do better with which treatment.
Doctors need to understand which treatment approach works best for different patients with chronic hepatitis B, and what patient characteristics help predict who will respond well to treatment. This information will help guide future treatment decisions.
You likely qualify if…
You likely don't qualify if…
You will be assigned to receive one of three treatment approaches for your hepatitis B. Throughout the study, you will have regular check-ups every three to six months where blood tests will measure your viral levels, liver function, and other markers. You may also be asked to provide samples of blood, urine, or stool, and in some cases a liver biopsy, to help researchers understand how well the treatment is working.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China
Enrollment target
~500 participants
Started
October 2021
Primary completion
October 2024
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years – 79 Years
Last updated on clinicaltrials.gov in May 2022.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Yan Huang
Xiangya Hospital of Central South University
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.